Drug Profile
Research programme: CNS disorder therapeutics - Aprecia Pharmaceuticals
Alternative Names: Oxcarbazepine - Aprecia Pharmaceuticals; Product 2 - Aprecia Pharmaceuticals; Product 3 - Aprecia Pharmaceuticals; Product 4 - Aprecia PharmaceuticalsLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Aprecia Pharmaceuticals
- Class Dibenzazepines; Pyrrolidinones; Small molecules
- Mechanism of Action Sodium channel antagonists; SV2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 23 Aug 2023 Preclinical development is ongoing in USA (Aprecia pharma pipeline August 2023)
- 28 Nov 2018 No recent reports of development identified for preclinical development in CNS-disorders in USA (PO, Tablet)
- 13 Dec 2017 Aprecia Pharmaceuticals enters into a partnership with Cycle Pharmaceuticals for development of orphan drugs